These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15177065)

  • 1. Apomorphine delays simple reaction time in Parkinsonian patients.
    Müller T; Benz S; Przuntek H
    Parkinsonism Relat Disord; 2002 Jun; 8(5):357-60. PubMed ID: 15177065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.
    Müller T; Benz S; Börnke C; Przuntek H
    Acta Neurol Scand; 2004 May; 109(5):348-54. PubMed ID: 15080862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delay of simple reaction time after levodopa intake.
    Müller T; Benz S; Börnke C
    Clin Neurophysiol; 2001 Nov; 112(11):2133-7. PubMed ID: 11682352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.
    van Hilten JJ; Wagemans EA; Ghafoerkhan SF; van Laar T
    Clin Neuropharmacol; 1997 Oct; 20(5):402-8. PubMed ID: 9331516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subcutaneous apomorphine injection: rescue management of motor fluctuations associated with levodopa-therapy].
    Yamada K; Miyauchi N; Kanda T
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):44-51. PubMed ID: 23302948
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclamol and parkinsonian fluctuations.
    Pirtosek Z; Merello M; Carlsson A; Stern G
    Clin Neuropharmacol; 1993 Dec; 16(6):550-4. PubMed ID: 9377590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep attacks with apomorphine.
    Homann CN; Suppan K; Wenzel K; Ivanic G; Kriechbaum N; Ott E
    Wien Klin Wochenschr; 2002 Jun; 114(10-11):430-1. PubMed ID: 12708100
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrent atrial fibrillation after subcutaneous apomorphine.
    Ardolino G; D'Adda E; Nobile-Orazio E
    Parkinsonism Relat Disord; 2008; 14(2):173-4; author reply 175. PubMed ID: 17632031
    [No Abstract]   [Full Text] [Related]  

  • 9. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The motor response to repeated apomorphine administration in Parkinson's disease.
    Hughes AJ; Bishop S; Stern GM; Lees AJ
    Clin Neuropharmacol; 1991 Jun; 14(3):209-13. PubMed ID: 2070362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
    Dewey RB; Hutton JT; LeWitt PA; Factor SA
    Arch Neurol; 2001 Sep; 58(9):1385-92. PubMed ID: 11559309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.
    Cavallieri F; Fraix V; Meoni S; Krack P; Moro E; Castrioto A
    J Neurol Sci; 2019 Sep; 404():44-46. PubMed ID: 31325667
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
    Bibbiani F; Costantini LC; Patel R; Chase TN
    Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
    LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
    Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
    Reuter I; Ellis CM; Ray Chaudhuri K
    Acta Neurol Scand; 1999 Sep; 100(3):163-7. PubMed ID: 10478579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 20. Apomorphine-induced penile erections in Parkinson's disease.
    O'Sullivan JD; Hughes AJ
    Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.